198 related articles for article (PubMed ID: 23332809)
1. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
[TBL] [Abstract][Full Text] [Related]
3. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
4. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
[TBL] [Abstract][Full Text] [Related]
5. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.
Vinetti M; Haufroid V; Capron A; Classen JF; Marchandise S; Hantson P
Clin Toxicol (Phila); 2011 Nov; 49(9):865-9. PubMed ID: 22077251
[TBL] [Abstract][Full Text] [Related]
6. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.
Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J
Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013
[TBL] [Abstract][Full Text] [Related]
7. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
8. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.
Launiainen T; Rasanen I; Vuori E; Ojanperä I
Int J Legal Med; 2011 May; 125(3):349-58. PubMed ID: 20432045
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
Ciusani E; Zullino DF; Eap CB; Brawand-Amey M; Brocard M; Baumann P
J Psychopharmacol; 2004 Dec; 18(4):559-66. PubMed ID: 15582923
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.
Karlsson L; Zackrisson AL; Josefsson M; Carlsson B; Green H; Kugelberg FC
Pharmacogenomics J; 2015 Apr; 15(2):165-71. PubMed ID: 25245581
[TBL] [Abstract][Full Text] [Related]
13. Distribution of venlafaxine and O-desmethylvenlafaxine in a fatal case.
Vignali C; Morini L; Chen Y; Stramesi C; Groppi A
Forensic Sci Int; 2014 Sep; 242():e48-e51. PubMed ID: 25086830
[TBL] [Abstract][Full Text] [Related]
14. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
17. Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
Drevin G; Picard N; Jousset N; Briet M; Abbara C
Forensic Sci Int Genet; 2021 Mar; 51():102433. PubMed ID: 33278816
[TBL] [Abstract][Full Text] [Related]
18. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Reis M; Lundmark J; Björk H; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]